People: Savient Pharmaceuticals Inc (SVNT.W)

Summary

Name	Age	Since	Current Position
Stephen Jaeger	67	2006	Non-Executive Independent Chairman of the Board
Louis Ferrari	59	2012	President, Chief Executive Officer, Director
John Hamill	47	2012	Chief Financial Officer, Senior Vice President, Treasurer
David Veitch	47	2012	President of Savient Pharma Ireland Limited
Richard Crowley	55	2011	Executive Vice President - Biopharmaceutical Operations
Philip Yachmetz	55	2008	Senior Vice President, General Counsel, Secretary
Kenneth Bahrt	59	2011	Senior Vice President, Chief Medical Officer
David Gionco	52	2012	Group Vice President, Chief Accounting Officer, Treasurer
David Meeker		2013	Director
David Norton	60	2012	Director
Robert Savage	59	2012	Director
Ginger Constantine	56	2009	Independent Director
Virgil Thompson	72	2000	Independent Director

» Insider Trading

Biographies

Name	Description
Stephen Jaeger	Mr. Stephen O. Jaeger serves as Non-Executive Independent Chairman of the Board of Savient Pharmaceuticals Inc. Mr. Jaeger has been a director since 2003, non-executive Chairman since 2006, is the chairperson of Compensation and Human Resources Committee and a member of Audit and Finance Committee. From March 1999 until April 2000, Mr. Jaeger was Chief Executive Officer of eBT International, Inc., a software company, and from June 2001 until his retirement in December 2005, he served as eBT’s President and Chief Executive Officer. From 1997 to 1998, Mr. Jaeger was Executive Vice President and Chief Financial Officer of The Clinical Communications Group, a medical education company, and from 1995 to 1997, he was Vice President, Chief Financial Officer and Treasurer of Applera Corporation, a life sciences company.
Louis Ferrari	Mr. Louis Ferrari has been appointed as President, Chief Executive Officer, Director of Savient Pharmaceuticals, Inc., effective July 9, 2012. Mr. Ferrari joined Savient in February 2011. He has over 30 years of experience in the pharmaceutical industry, including in product launches, new product development, international marketing, sales management, sales training, licensing and acquisitions and clinical trials. Mr. Ferrari previously held the position of Executive Vice President, President North American Commercial Operations at Savient. Prior to joining Savient, Mr. Ferrari had a long career of increasing responsibility at Johnson and Johnson, where he most recently served as Vice President of Oncology and Nephrology, Sales and Marketing. In that position, he was responsible for sales of Procrit and Doxiland the impending launch of Abiraterone for Chemotherapy Resistant Metastatic Prostate Cancer. Mr. Ferrari served on the Management Board for both Ortho Biotech and Centocor Ortho Biotech from 2004 to 2011. He earned his Bachelor of Science in Pharmacy from the Brooklyn College of Pharmacy and a Masters of Business Administration from Adelphi University.
John Hamill	Mr. John P. Hamill has been appointed as Chief Financial Officer, Senior Vice President of Savient Pharmaceuticals, Inc., effective September 24, 2012. Most recently, Mr. Hamill served as Chief Financial Officer of PharmaNet Development Group, Inc., a global supplier of drug development services, and its wholly owned subsidiary PharmaNet, Inc., where he directed financial and administrative operations. Prior to PharmaNet, Mr. Hamill held senior financial management positions of increasing responsibility and breadth at Omnicare Clinical Research and financial management positions at Rhone-Poulenc, Freedom Chemical Company, International Paper and Johnson & Johnson. Mr. Hamill holds a Bachelor of Science in Accounting/Business and Computer Science from DeSales University, is a Certified Public Accountant and is a member of Pennsylvania and American Institutes of Certified Public Accountants.
David Veitch	Mr. David Veitch serves as President of Savient Pharma Ireland Limited., a subisidiary of Savient Pharmaceuticals Inc., since January 2012. Mr. Veitch is responsible for establishing, building the Company’s European regional organization to commercially launch and drive the future growth of KRYSTEXXA. Mr. Veitch joins Savient with over 24 years of pharmaceutical industry experience at Bristol-Myers Squibb and SmithKline Beecham Pharmaceuticals, and has knowledge across many therapy areas including: oncology, virology, CV-Metabolism, CNS and Immunology. Most recently he served as Senior Vice President of European Marketing & Brand Commercialization at Bristol-Myers Squibb, where he was responsible for the brand commercial organization for Europe across all disease areas and generating sales of $4 to $5 billion. Prior to that, Mr. Veitch spent ten years serving in a number of leadership positions at Bristol-Myers Squibb. Before his time at Bristol, Mr. Veitch spent ten years in a variety of managerial roles at SmithKline Beecham Pharmaceuticals. He received his Bachelor of Science degree from Bristol University in Bristol, England.
Richard Crowley	Mr. Richard Crowley serves as Executive Vice President - Biopharmaceutical Operations of Savient Pharmaceuticals Inc., since April 2011. Mr. Crowley leads the overall management of the Company’s manufacturing, regulatory, quality, product management and KRYSTEXXA product teams. Mr. Crowley previously served as Senior Vice President of Biopharmaceutical Operations at ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company. Prior to that, Mr. Crowley served as Vice President of Manufacturing and General Manager at ImClone Systems. Mr. Crowley has also held positions at BASF Bioresearch Corporation, Genencor International, Eastman Kodak Company and Monsanto Company.
Philip Yachmetz	Mr. Philip K. Yachmetz serves as Senior Vice President, General Counsel, Secretary of Savient Pharmaceuticals Inc., since November 2008. He previously served as Executive Vice President and Chief Business Officer from February 2006 through November 2008 and as Senior Vice President—Corporate Strategy, General Counsel and Secretary from May 2004 until February 2006. From 2000 until 2004, Mr. Yachmetz was Vice President, General Counsel and Secretary of Progenics Pharmaceuticals. From 1998 to 2000, he was Senior Vice President, Business Development, General Counsel and Secretary at CytoTherapeutics (now StemCells), a stem cell therapeutics discovery company. Mr. Yachmetz founded and served from 1997 to 1998 as Managing Director of Millennium Venture Management, a business consulting and advisory firm to the pharmaceutical, healthcare and high technology industries. From 1989 to 1996, he held legal positions of increasing responsibility at Hoffmann-La Roche, a pharmaceutical company. Mr. Yachmetz is an attorney admitted to the bar in New Jersey and New York.
Kenneth Bahrt	Dr. Kenneth M. Bahrt, M.D., serves as Senior Vice President, Chief Medical Officer of Savient Pharmaceuticals Inc. Dr. Bahrt leads the overall management of Savient’s clinical development, drug safety and medical affairs teams. Dr. Bahrt previously served as Therapeutic Area Head for US Medical Affairs (Immunology) at Genentech, a biotechnology company. He also previously served as Global Medical Director (Inflammation and Immunology) for F. Hoffmann—La Roche, Inc, a pharmaceutical and diagnostics company. Additionally, Dr. Bahrt worked in leadership positions of increasing breadth and responsibility at Bristol Meyers Squibb Co., a global biopharmaceutical company, where he was the Executive Director of Global Medical Affairs (Immunology), and Pfizer, a biopharmaceutical company, where he served as Medical Director and Team Leader for rheumatology portfolio products. Prior to joining the pharmaceutical industry, Dr. Bahrt had a rheumatology practice for 15 years. Dr. Bahrt is board certified rheumatologist.
David Gionco	Mr. David G. Gionco is the Group Vice President, Chief Accounting Officer, Treasurer of Savient Pharmaceuticals, Inc. He joined the Company in February 2006 as Vice President of Corporate Finance and Controller, and served as the Company's Group Vice President - Chief Financial Officer & Treasurer from February 2009 until September 2011, and Group Vice President - Finance from September 2011 to May 2012. From August 2004 to February 2006, Mr. Gionco served as Acting Chief Financial Officer/Director of Finance and Controller of Odyssey Pharmaceuticals, a specialty pharmaceuticals company. From July 2003 through August 2004, he served as the Director of Finance for Progenics Pharmaceuticals. Mr. Gionco has spent more than 21 years in the pharmaceutical industry in various audit, corporate accounting, financial planning, finance and controller roles at several pharmaceutical companies, including Medco Health Solutions, Inc. and Merck & Co. In addition, Mr. Gionco has seven years of financial auditing experience with Edward Isaacs & Company, a public accounting firm that was acquired in 2000 by McGladrey & Pullen. Mr. Gionco holds a B.S. in Accounting from Fairleigh Dickinson University and an MBA from Rutgers University.
David Meeker	Dr. David P. Meeker, M.D., has been appointed as Director of Savient Pharmaceuticals, Inc., effective January 7, 2013. Dr. Meeker was appointed President and Chief Executive Officer of Genzyme, a Sanofi Company, in October 2011. Prior to this, he held key positions of increasing responsibility at Genzyme first within Research and Development and then within the commercial organization. Most recently he served as Chief Operating Officer, in which capacity he was responsible for Genzyme’s commercial organization and played an important role in the company’s integration with Sanofi. Previous positions at Genzyme included President of the Global Rare Disease Business, in which role Dr. Meeker oversaw the global launches of Aldurazyme®, Fabrazyme®, and Myozyme®. Prior to joining Genzyme, Dr. Meeker served as the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and as an assistant professor of medicine at Ohio State University. He currently is a Board member of the Biotechnology Industry Organization and of Prize4Life. Dr. Meeker received his M.D. degree from the University of Vermont Medical School and completed the Advanced Management Program at Harvard Business School.
David Norton	Mr. David Y. Norton serves as Director of Savient Pharmaceuticals Inc. He resigned as Interim Chief Executive Officer of the Company, effective July 9, 2012. He has been a director since September 2011 and Interim Chief Executive Officer since February 2012. From May 2009 until his retirement in September 2011, Mr. Norton was Company Group Chairman, Global Pharmaceuticals for Johnson & Johnson, a global pharmaceutical company. Mr. Norton previously served as Johnson & Johnson’s Company Group Chairman, Worldwide Commercial and Operations for the CNS, Internal Medicine and Virology franchise from June 2006 to April 2009, and held executive positions of increasing scope with Johnson & Johnson since 2001, and a wide range of management positions of increasing responsibility in Europe, Australia, New Zealand and the United States with Janssen Pharmaceutica prior to its acquisition by Johnson & Johnson.
Robert Savage	Mr. Robert G. Savage has been appointed as Director of Savient Pharmaceuticals, Inc. effective December 5, 2012. Mr. Savage is currently President and CEO of Strategic Imagery LLC, a consulting company of which he is the principal. Previously, Mr. Savage was Group Vice President and President of the Worldwide General Therapeutics & Inflammation Business of Pharmacia Corporation from 2002 until its acquisition by Pfizer, Inc. in 2003. Prior to that role, he held several senior positions with Johnson & Johnson, including Worldwide Chairman of the Pharmaceuticals Group, Company Group Chairman for the North American pharmaceuticals business, President of Ortho-McNeil Pharmaceuticals and Vice President of Sales and Marketing. Earlier in his career, he served in a variety of senior marketing, operations, business development and strategic planning positions for Hoffmann-La Roche, Inc. Mr. Savage currently serves as a director of EpiCept Corporation, Nuovo Biologics and The Medicines Company. Mr. Savage received a B.S. in Biology from Upsala College and an M.B.A. from Rutgers University.
Ginger Constantine	Dr. Ginger D. Constantine M.D., serves as an Independent Director of Savient Pharmaceuticals Inc. since June 2009. She is a member of Nominating and Corporate Governance Committee. Since June 2010, Dr. Constantine has been a consultant with Endo-Rheum Consultants, a medical/clinical consulting firm. Until March 2010, when it was acquired by Pfizer Pharmaceuticals, Dr. Constantine served as Vice President of Women’s Health & Bone Repair Medical Research at Wyeth Research, a division of Wyeth Pharmaceuticals, a pharmaceutical company, and held Vice President positions with Wyeth since 2000. Dr. Constantine has held various management positions of increasing responsibility in the therapeutic areas of rheumatology, metabolism and bone repair within the Wyeth Pharmaceuticals and Wyeth Research organizations. Prior to joining Wyeth, Dr. Constantine was a practicing physician specializing in Rheumatology and Internal Medicine. Dr. Constantine obtained her medical degree from Temple University and completed her Rheumatology Fellowship at the University of Pennsylvania. She is currently a member of the American College of Rheumatology and a committee member for The Endocrine Society as well as various medical societies, including the American Medical Association, American Rheumatism Association and the Pennsylvania Medical Society. Dr. Constantine has over 15 years of management experience in the pharmaceutical industry and is a licensed rheumatologist.
Virgil Thompson	Mr. Virgil D. Thompson serves as an Independent Director of Savient Pharmaceuticals Inc., since 1994. He s chairperson of Nominating and Corporate Governance Committee and a member of Audit and Finance Committee. Since July 2009, Mr. Thompson has served as Chief Executive Officer of Spinnaker Biosciences, Inc., a private ophthalmic drug delivery company. From 2002 to July 2007, Mr. Thompson was President and Chief Executive Officer of Angstrom Pharmaceuticals, Inc., a pharmaceutical company, and served on its board of directors until 2009. From 2000 to 2002, Mr. Thompson was President, Chief Executive Officer and a director of Chimeric Therapies, Inc., a biotechnology company, and he was President and Chief Operating Officer from 1999 to 2000. From 1996 to 1999, Mr. Thompson was President and Chief Executive Officer of Cytel Corporation, a biotechnology company. Mr. Thompson is chairperson of the board of directors of Aradigm Corporation, an emerging specialty pharmaceutical company, and a member of its compensation, nominating and corporate governance and audit committees. Mr. Thompson is chairperson of the board of directors of Questcor Pharmaceuticals, Inc., a biopharmaceutical company, and serves on its compensation and audit committees. Mr. Thompson is also on the board of directors of Soligenix, Inc., a biopharmaceutical company, and serves on its compensation and audit committees. Mr. Thompson has over 40 years of senior management and financial oversight experience in the pharmaceutical and biopharmaceutical industries

Basic Compensation

Name	Fiscal Year Total
Stephen Jaeger	--
Louis Ferrari	--
John Hamill	--
David Veitch	--
Richard Crowley	1,554,830
Philip Yachmetz	840,100
Kenneth Bahrt	1,451,800
David Gionco	685,565
David Meeker	--
David Norton	--
Robert Savage	--
Ginger Constantine	--
Virgil Thompson	338,352

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Stephen Jaeger	0	0
Louis Ferrari	0	0
John Hamill	0	0
David Veitch	0	0
Richard Crowley	0	0
Philip Yachmetz	135,000	657,113
Kenneth Bahrt	0	0
David Gionco	7,500	87,225
David Meeker	0	0
David Norton	0	0
Robert Savage	0	0
Ginger Constantine	0	0
Virgil Thompson	235,000	1,910,004

Insider Trading

Name	Shares Traded	Price
BAHRT KENNETH	1,250	$0.74
CROWLEY RICHARD	2,485	$0.74
GIONCO DAVID G	1,560	$0.93
GIONCO DAVID G	29,000	$0.00
FERRARI LOUIS	375	$0.99
YACHMETZ PHILIP K	27,297	$1.01
CROWLEY RICHARD	30,000	$1.05
FERRARI LOUIS	59,000	$1.01
YACHMETZ PHILIP K	3,203	$1.02
FERRARI LOUIS	3,200	$1.02
CROWLEY RICHARD	18,900	$1.01
BAHRT KENNETH	21,700	$1.04
BAHRT KENNETH	7,300	$1.01
CROWLEY RICHARD	2,415	$1.02
BAHRT KENNETH	1,300	$1.03
YACHMETZ PHILIP K	1,283	$1.14
MEEKER DAVID P	12,644	$1.17
SAVAGE ROBERT G	16,149	$1.14
FERRARI LOUIS	950	$1.16
BAHRT KENNETH	1,000	$1.45
CROWLEY RICHARD	2,010	$1.45
HAMILL JOHN P	100,000	$2.92
FERRARI LOUIS	2,434	$1.12
FERRARI LOUIS	984	$1.00
CROWLEY RICHARD	2,500	$0.62

» Full list on Insider Trading

People: Savient Pharmaceuticals Inc (SVNT.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: